EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and Tolerability of the Gut Bacterium Phascolarctobacterium faecium DSM 32890

Maria Tamayo iD, Veronica Tolosa-Enguis iD, Blanca Alabadi iD, Marta Olivares iD, Sergio Romera, Leticia Orti, Elisabet Terrado iD, Alejandra Flor Duro, Carlos Morillas iD, Pilar Codoñer iD, José T Real, Yolanda Sanz iD

Nutrients · 2026

DOI: 10.3390/nu18030498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2026. Verfasst von Maria Tamayo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Microbiome Innovation in Nutrition and Health Research Unit (INNOBIOME), Institute of Agrochemistry and Food Technology, Spanish National Research Co…. Hauptthemen laut MEDLINE: Probiotics, Gastrointestinal Microbiome, Bacillota. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Innovation and Universities (MCIU, grants), Severo Ochoa 565 Center of Excellence to IATA-CSIC from MCIN/AEI, Agencia Valenciana de la Innovación (AVI/IVACE) de la Generalitat Valenciana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The prevalence of the commensal gut bacterium species, Phascolarctobacterium faecium, has been associated with normal weight in humans. Preclinical evidence suggests that the strain P. faecium DSM 32890 exerts beneficial effects on metabolic and immune function in diet-induced obesity. Herein, we aimed to evaluate the safety and tolerability of this strain in a preclinical study and a pilot interventional trial in humans.

Methods

A repeated-dose oral toxicity study of 28 days was performed in Wistar rats (male and female), during which adverse signs and clinical outcomes were assessed, along with histological, hematologic, biochemical, and immune markers. Subsequently, a pilot human intervention trial was conducted, including 20 participants (11 overweight and 9 normal weight) who received P. faecium DSM 32890 daily for 15 days. Body composition, dietary intake, physical activity, clinical data, perceived health, gastrointestinal symptoms, and blood analyses were assessed to determine tolerability and identify potential adverse effects.

Results

In rats, the administration of the bacterium did not cause behavioral, physiological, histologic, immune, or biochemical alterations. In humans, there was no evidence of adverse effects on general health, hematological and biochemical profiles, bowel habits, or gastrointestinal symptoms. Overweight participants experienced reductions in flatulence and nausea after the intervention.

Conclusions

The consumption of P. faecium DSM 32890 did not raise safety concerns and was well tolerated in rats and humans. The findings represent a step forward in the path toward future, longer-term studies to explore the potential efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsGastrointestinal MicrobiomeBacillotaAnimalsMaleRats, WistarFemaleHumansRatsPilot ProjectsAdultOverweightMiddle AgedObesity

Stichwörter der Autor:innen

Phascolarctobacterium faeciumgut microbiomeobesitysafety and tolerabilitytype 2 diabetes

Autor:innen und Institutionen

  • Microbiome Innovation in Nutrition and Health Research Unit (INNOBIOME), Institute of Agrochemistry and Food Technology, Spanish National Research Council (IATA-CSIC), 46980 Valencia, Spain.
  • INCLIVA Biomedical Research Institute, 46010 Valencia, Spain.
  • CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain.
  • Endocrinology and Nutrition Service, University Hospital Doctor Peset, 46017 Valencia, Spain.
  • Endocrinology and Nutrition Service, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
  • Department of Medicine, University of Valencia, 46010 Valencia, Spain.

ORCID-Profile: Maria Tamayo, Veronica Tolosa-Enguis, Blanca Alabadi, Marta Olivares, Elisabet Terrado, Carlos Morillas, Pilar Codoñer, Yolanda Sanz

Förderung

  • Ministry of Science, Innovation and Universities (MCIU, grants)
  • Severo Ochoa 565 Center of Excellence to IATA-CSIC from MCIN/AEI
  • Agencia Valenciana de la Innovación (AVI/IVACE) de la Generalitat Valenciana
  • MCIN/AEI

Zitieren

APA

Tamayo, M., Tolosa-Enguis, V., Alabadi, B., Olivares, M., Romera, S., Orti, L., Terrado, E., Flor Duro, A., Morillas, C., Codoñer, P., Real, J. T., & Sanz, Y. (2026). Safety and Tolerability of the Gut Bacterium Phascolarctobacterium faecium DSM 32890. Nutrients. https://doi.org/10.3390/nu18030498

Vancouver

Tamayo M, Tolosa-Enguis V, Alabadi B, Olivares M, Romera S, Orti L, et al. Safety and Tolerability of the Gut Bacterium Phascolarctobacterium faecium DSM 32890. Nutrients. 2026. doi:10.3390/nu18030498

BibTeX
@article{Tamayo2026,
  author = {Tamayo, Maria and Tolosa-Enguis, Veronica and Alabadi, Blanca and Olivares, Marta and Romera, Sergio and Orti, Leticia and Terrado, Elisabet and Flor Duro, Alejandra and Morillas, Carlos and Codoñer, Pilar and Real, José T and Sanz, Yolanda},
  title = {Safety and Tolerability of the Gut Bacterium Phascolarctobacterium faecium DSM 32890},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18030498}
}
Kostenlos starten →